Edwards scores CE Mark for transfemoral heart valve delivery system

Justine Varieur Cadet | | Health Imaging | Diagnostic Imaging
Edwards Lifesciences, a heart valve company, has received CE Mark approval for European commercial sales of its RetroFlex 3 transfemoral delivery system for its Sapien transcatheter heart valve.

The RetroFlex 3 delivery system is designed to control the navigation of the valve, through the incorporation of the valve expansion balloon directly into the delivery system's flexible tip, the company said. The new design also facilitates the crossing of the patient's native aortic valve, which in this population is calcified as a result of severe aortic stenosis, according to the St-Prex, Switzerland-based Edwards.

The Edwards Sapien transcatheter heart valve with the RetroFlex 3 transfemoral and Ascendra transapical delivery systems is approved for commercial sale in Europe. In the U.S., the Edwards Sapien valve is an investigational device that is being studied in the PARTNER (Placement of AoRTic traNscathetER valves) randomized clinical trial, and is not available for sale.

Justine Varieur Cadet

Related Content

First human X-rays in space to take place during upcoming SpaceX mission
Mycoplasma pneumonia: Experts highlight imaging findings linked to the pediatric diagnosis
AI rules out abnormal findings on chest X-rays, significantly reducing workloads
Older adults among the walking wounded with incident TBI
Philips moves digital pathology to the cloud with AWS
PHOTO GALLERY: What does fetal medical imaging look like?

Around the web

Cardiovascular Business
GE HealthCare launches new cardiac CT scanner with advanced AI capabilities

GE HealthCare designed the new-look Revolution Vibe CT scanner to help hospitals and health systems embrace CCTA and improve overall efficiency.

Cardiovascular Business
Bracco updates HeartSee coronary flow capacity software with new diagnostic features

Clinicians have been using HeartSee to diagnose and treat coronary artery disease since the technology first debuted back in 2018. These latest updates, set to roll out to existing users, are designed to improve diagnostic performance and user access.

Cardiovascular Business
Key trends in diagnostic heart testing: CT on the rise as some traditional techniques fall out of favor

The cardiac technologies clinicians use for CVD evaluations have changed significantly in recent years, according to a new analysis of CMS data. While some modalities are on the rise, others are being utilized much less than ever before.